AI is transforming drug development—where has it made the biggest impact, and where is it headed next? In their latest white paper, "Inflection Points of Artificial Intelligence in Drug Development," Luka Jelcic and Anastasia Christianson, Ph.D., explore these questions, with valuable contributions from Rafael Rosengarten.The paper examines how AI adoption in biopharma has evolved, the rise of AI-first companies, and shifting partnership dynamics based on ~180 collaborations. It also analyzes funding trends over the past five years, the growing pipelines of AI-driven drug programs, and a unique approach to assessing target novelty. Looking ahead, it explores the potential of quantum computing to further enhance AI’s impact in drug R&D.

‍